FDA Advisory Panel’s Decision on Peptides Sparks Concern

Recent moves by an FDA advisory panel to ease restrictions on peptides have ignited concerns about the safety of these unproven therapies. The debate centers on whether economic and political influences compromised the panel’s decision, raising questions about public trust in the FDA.

Peptides, comprised of short amino acid chains, serve as biological receptors in the body. Notable examples include insulin and GLP-1 therapies, which have transformed medical treatment through their scientific backing. Presently, research is ongoing into peptides’ potential in tissue repair.

“Peptide-Based Therapies Show Promise in Chronic and Acute Wound Care,” declared a recent health article.

However, promise should not be confused with proven safety or effectiveness. Many peptides marketed by wellness clinics and online sources lack rigorous scientific evaluation. Concerns about their long-term safety and impact remain, necessitating extensive research and analysis.

Despite limited data, the FDA panel supported adding certain peptides to drug compounding lists, potentially broadening access. This decision seemed orchestrated, not resulting from extensive scientific evidence. Of the 14-panel members, eight were appointed by Health and Human Services Secretary Robert F. Kennedy, Jr.’s office, with six having affiliations with clinics offering peptides, hinting at conflicts of interest.

These conflicts erode trust in U.S. health entities. The credibility of the panel and FDA is at risk given Kennedy’s involvement in selecting panel members. Peptides, reportedly a focus for Kennedy, have been personally endorsed.

“I’m a big fan,” Kennedy remarked on a podcast. “I’ve used them myself effectively on injuries.” Kennedy, lacking medical training, should not let personal choices shape federal policy.

The FDA is expected to ensure drug safety, and greater research is needed on peptide interactions and potential risks before public recommendation. Public health experts caution against online peptide promotion without expert vetting.

Dr. Pieter Cohen of Harvard Medical School expressed skepticism, noting any benefits claimed “are divorced from data.” He advises against self-injecting peptides.

Peptides join a list of health initiatives supported by Kennedy, often based on his health practices rather than evidence-backed science. Kennedy has similarly encouraged increased access to controversial treatments, including testosterone and stem cell therapies.

Scientific guidance, rather than alternative health practices of politically powerful figures, should dictate government health policies. Federal health agencies must reinforce their independence, prevent conflicts of interest, and provide clear insights into the limitations and risks of therapies under consideration. Public health experts, dedicated to drug safety research, should be leading advisory panels to ensure science-driven recommendations safeguard Americans.

Lyndon Haviland, DrPH, MPH, is recognized as a distinguished scholar at the CUNY School of Public Health and Health Policy.